On April 2, China Regenerative Medicine (08158.HK) announced that for the year ended December 31, 2023, revenue was approximately HK$69.49 million, an increase of 67.29% over the previous year; gross profit decreased by 48.37% from the previous year to approximately HK$19.42 million; the company's equity holders should account for the current year's loss of approximately HK$108 million (2022: profit of HK$4.56 million), with a basic loss of HK$37.60 per share.
中国再生医学(08158.HK)：2023年股东应占亏损约1.08亿港元
China Regenerative Medicine (08158.HK): Shareholders' share loss of approximately HK$108 million in 2023
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.